Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXI NASDAQ:COCP NASDAQ:ORMP OTCMKTS:PVOTF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.33$0.40$0.15▼$0.97$1.07M-0.215,944 shs686 shsCOCPCocrystal Pharma$1.00$1.23$0.86▼$2.67$13.72M1.42108,065 shs73,263 shsORMPOramed Pharmaceuticals$3.88$3.96$1.98▼$5.01$158.79M1.26177,070 shs148,935 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics0.00%+1.75%+17.25%+12.28%+25.47%COCPCocrystal Pharma0.00%+0.01%-11.95%-3.40%-35.81%ORMPOramed Pharmaceuticals0.00%+0.26%-11.42%+11.17%+80.47%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.33$0.40$0.15▼$0.97$1.07M-0.215,944 shs686 shsCOCPCocrystal Pharma$1.00$1.23$0.86▼$2.67$13.72M1.42108,065 shs73,263 shsORMPOramed Pharmaceuticals$3.88$3.96$1.98▼$5.01$158.79M1.26177,070 shs148,935 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics0.00%+1.75%+17.25%+12.28%+25.47%COCPCocrystal Pharma0.00%+0.01%-11.95%-3.40%-35.81%ORMPOramed Pharmaceuticals0.00%+0.26%-11.42%+11.17%+80.47%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/ACOCPCocrystal Pharma 1.00SellN/AN/AORMPOramed Pharmaceuticals 2.00HoldN/AN/APVOTFBetterLife Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ORMP, COCP, PVOTF, and ATXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)6/8/2026COCPCocrystal Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026COCPCocrystal Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)3/27/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/ACOCPCocrystal PharmaN/AN/AN/AN/A$0.46 per shareN/AORMPOramed Pharmaceuticals$2M79.40$0.09 per share42.77$5.02 per share0.77PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$0.530.02N/AN/AN/A-471.57%-296.50%8/10/2026 (Estimated)COCPCocrystal Pharma-$8.83M-$0.73N/AN/AN/AN/A-150.61%-97.86%8/13/2026 (Estimated)ORMPOramed Pharmaceuticals$64.05M$2.591.50N/AN/AN/A-5.37%-4.83%8/13/2026 (Estimated)PVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ALatest ORMP, COCP, PVOTF, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026COCPCocrystal Pharma-$0.15-$0.17-$0.02-$0.17$0.23 million$0.23 million3/31/2026Q4 2025COCPCocrystal Pharma-$0.18-$0.17+$0.01-$0.17N/AN/A3/27/2026Q4 2025ORMPOramed Pharmaceuticals-$0.08-$0.06+$0.02$0.24$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals$0.256.44%N/A9.65%N/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70COCPCocrystal PharmaN/A2.662.66ORMPOramed PharmaceuticalsN/A6.456.45PVOTFBetterLife PharmaN/A3.623.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%COCPCocrystal Pharma6.72%ORMPOramed Pharmaceuticals12.73%PVOTFBetterLife PharmaN/AInsider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics8.60%COCPCocrystal Pharma39.40%ORMPOramed Pharmaceuticals17.80%PVOTFBetterLife Pharma34.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.30 million2.02 millionNot OptionableCOCPCocrystal Pharma1013.79 million8.36 millionNot OptionableORMPOramed Pharmaceuticals1040.93 million33.64 millionOptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableORMP, COCP, PVOTF, and ATXI HeadlinesRecent News About These CompaniesBetterLife Pharma targets global partners for BETR-001 at JPM Week forumsJanuary 6, 2026 | msn.comBetterLife Pharma Director and Audit Chair Robert Metcalfe ResignsDecember 23, 2025 | tipranks.comBetterLife Pharma Announces Engagement with Shanghai-Based YAFO CapitalDecember 11, 2025 | finance.yahoo.comBetterLife Pharma Inc.May 19, 2025 | barrons.comBetterLife appoints Steven Sangha to board of directorsApril 1, 2025 | markets.businessinsider.comBetterLife Pharma Achieves Key Cardiac Safety MilestoneNovember 25, 2024 | markets.businessinsider.comBetterLife Pharma Inc BETRNovember 2, 2024 | morningstar.comMOptimistic Buy Rating for BridgeBio Pharma’s BBP-812: Promising Phase 1/2 Results in Canavan Disease TherapyOctober 25, 2024 | markets.businessinsider.comBridgeBio Pharma’s BBP-812 Trial Shows Promise for Canavan Disease Amidst Focus on AcoramidisOctober 25, 2024 | markets.businessinsider.comBetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001October 23, 2024 | tmcnet.comWith election nearing, BMO analysts don't expect major pharma shake-ups from either candidateOctober 14, 2024 | fiercepharma.comFAbortion, immigration, drug prices: Where Missouri’s candidates for U.S. Senate stand on the issuesOctober 13, 2024 | msn.comDemocrats snatch a major political football away from Republicans: freedomAugust 28, 2024 | yahoo.comRAMM Pharma Corp. (RAMM.CN)August 22, 2024 | uk.finance.yahoo.com‘Their skin was peeling off from the chemical burns’: Andhra reactor blast that killed 14 leaves trail of broken homesAugust 21, 2024 | indianexpress.comIRewarding careers for animal loversAugust 13, 2024 | deccanherald.comDState, city leaders announce deal for quantum technology facility on Chicago’s South SideJuly 27, 2024 | courthousenews.comC$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management DrugsApril 26, 2024 | msn.comJardiance and Ofev propel Boehringer’s human pharma salesApril 17, 2024 | msn.comVertex Pharma scientist talks about the long road to developing non-addictive painkillersApril 15, 2024 | abcnews.go.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, COCP, PVOTF, and ATXI Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.33 0.00 (0.00%) As of 06/18/2026 03:59 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Cocrystal Pharma NASDAQ:COCP$1.00 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.98 -0.01 (-1.11%) As of 06/18/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Oramed Pharmaceuticals NASDAQ:ORMP$3.88 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.92 +0.04 (+1.01%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.BetterLife Pharma OTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
